influenza
viru
infect
result
respiratori
ill
contribut
high
rate
morbid
mortal
human
particularli
children
elderli
immunocompromis
individu
three
influenza
pandem
occur
centuri
spanish
flu
asian
influenza
hong
kong
influenza
one
recent
occur
centuri
pandem
besid
pandem
influenza
season
epidem
influenza
also
great
concern
caus
approxim
million
sever
ill
death
annual
worldwid
control
spread
influenza
remain
major
challeng
undeni
vaccin
confer
protect
influenza
effect
current
three
type
influenza
vaccin
avail
market
inactiv
influenza
viru
vaccin
iiv
live
attenu
influenza
viru
vaccin
laiv
recombin
vaccin
iiv
good
induc
system
immun
respons
ineffect
stimul
mucos
immun
respons
laiv
hand
induc
system
mucos
immun
respons
howev
associ
risk
attenu
viru
revert
back
highli
virul
form
thu
caus
infect
case
laiv
transmiss
recipi
previous
report
addit
studi
shown
laiv
increas
risk
wheez
within
day
vaccin
children
recombin
vaccin
potenti
advantag
especi
event
pandem
due
quick
product
potenti
vaccin
administ
intramuscularli
therefor
induc
immun
respons
similar
iiv
howev
seriou
advers
event
associ
vaccin
vasovag
syncop
pericardi
effus
bell
palsi
previous
report
taken
togeth
influenza
vaccin
current
avail
present
sever
drawback
includ
limit
abil
stimul
mucos
immun
without
compromis
safeti
issu
influenza
viru
initi
infect
respiratori
tract
mucos
surfac
would
advantag
vaccin
abl
induc
mucos
immun
respons
mainli
secretori
iga
siga
one
current
strategi
mucos
vaccin
research
target
stimul
mucos
immun
oral
administr
antigen
use
lactococcu
lacti
deliveri
platform
l
lacti
gener
recogn
safe
bacterium
appli
mucos
vaccin
research
due
noncolon
nonpathogen
properti
recent
l
lacti
extens
explor
effect
oralbas
vaccin
vehicl
deliv
antigen
sever
virus
bacteria
parasit
studi
shown
l
lacti
express
display
antigen
capabl
induc
strong
system
well
mucos
immun
respons
consid
role
mucos
immun
protect
influenza
previous
develop
nonrecombin
l
lacti
surfac
display
influenza
hemagglutinin
use
nacetylmuramidas
acma
bind
domain
anchor
bacteri
cell
wall
amount
bound
l
lacti
improv
use
singlechain
variabl
fragment
peptid
linker
link
acma
bind
domain
present
studi
extend
previou
work
optim
bind
paramet
amount
recombin
protein
ad
l
lacti
durat
bind
buffer
use
bind
assess
specif
immun
respons
elicit
upon
oral
immun
nonrecombin
l
lacti
surfac
display
mice
addit
protect
efficaci
lethal
dose
challeng
influenza
viru
also
assess
procedur
involv
anim
review
approv
faculti
medicineinstitut
anim
care
use
committe
fomiacuc
ethic
refer
ketaminexylazin
ketamin
mgkg
xylazin
mgkg
use
anesthet
anim
studi
overdos
ketaminexylazin
ketamin
mgkg
xylazin
mgkg
given
euthan
anim
studi
l
lacti
display
recombin
protein
prepar
previous
describ
briefli
overnight
cultur
l
lacti
subcultur
broth
incub
read
reach
l
lacti
cultur
ml
centrifug
min
cell
pellet
obtain
resuspend
fresh
broth
ml
subsequ
refold
recombin
protein
prepar
previous
describ
ad
cell
suspens
incub
h
cell
wash
phosphat
buffer
salin
pb
thrice
centrifug
min
cell
pellet
eventu
resuspend
pb
optim
perform
improv
bind
l
lacti
vari
bind
paramet
specif
amount
recombin
protein
ad
equal
number
l
lacti
cell
durat
bind
h
type
bind
buffer
pb
factor
may
influenc
bind
recombin
protein
onto
l
lacti
includ
ph
temperatur
examin
factor
may
affect
integr
cell
membran
biolog
process
l
lacti
may
affect
bind
recombin
protein
bacteri
cell
wall
bind
l
lacti
cell
premix
stain
analyz
use
flow
cytometri
previous
describ
briefli
cell
fix
wv
paraformaldehyd
min
block
wv
bovin
serum
albumin
bsa
min
subsequ
cell
incub
mous
monoclon
antipolyhistidin
sigmaaldrich
usa
dilut
h
follow
incub
alexa
goat
antimous
igg
invitrogen
life
technolog
usa
dilut
dark
h
cell
wash
pb
step
thrice
recov
centrifug
min
cell
eventu
suspend
ml
pb
examin
stain
cell
use
fluorescenceactiv
cell
sort
fac
canto
ii
flow
cytomet
bd
bioscienc
usa
total
cell
fall
gate
defin
forward
angl
light
scattersid
angl
light
scatter
plot
acquir
determin
posit
cell
count
mean
fluoresc
intens
mfi
l
lacti
display
recombin
protein
prepar
use
optim
condit
determin
earlier
scaledup
proport
increas
amount
recombin
protein
l
lacti
cell
use
bind
l
lacti
display
resuspend
endotoxinfre
pb
concentr
cfuml
cfuml
studi
group
b
respect
construct
nonrecombin
l
lacti
display
name
six
eightweeksold
specificpathogenfre
femal
balbc
mice
purchas
invivo
pte
ltd
singapor
anim
hous
specificpathogenfre
condit
free
access
food
water
accord
associ
assess
accredit
laboratori
anim
care
intern
fomiacuc
guidelin
univers
malaya
total
two
studi
group
perform
evalu
immunogen
studi
group
mice
n
immun
oral
ml
cfu
endotoxinfre
pb
intragastr
lavag
consecut
day
immun
regimen
repeat
thrice
week
interv
studi
group
b
mice
n
immun
oral
ml
cfu
endotoxinfre
pb
consecut
day
immun
regimen
repeat
thrice
week
interv
posit
control
emulsifi
complet
freund
adjuv
cfa
sigmaaldrich
usa
administ
subcutan
group
mice
n
immun
repeat
thrice
week
interv
use
incomplet
freund
adjuv
ifa
sigmaaldrich
usa
instead
cfa
studi
group
blood
faec
collect
week
last
immun
thereaft
mice
euthan
intraperiton
inject
overdos
ketaminexylazin
sampl
small
intestin
bronchoalveolar
lavag
bal
nasal
fluid
collect
studi
group
b
blood
faecal
pellet
collect
mice
studi
group
b
euthan
kept
viral
challeng
briefli
blood
sampl
collect
via
tail
vein
serum
obtain
centrifug
min
faecal
pellet
mg
resuspend
ml
steril
pb
contain
mm
phenylmethanesulfonyl
fluorid
pmsf
vortex
vigor
faecal
extract
obtain
centrifug
min
small
intestin
harvest
flush
thrice
ml
pb
contain
mm
pmsf
sampl
small
intestin
obtain
follow
centrifug
min
bal
nasal
fluid
collect
previous
describ
minor
modif
briefli
mous
trachea
cannul
intraven
cathet
bd
bioscienc
usa
connect
syring
bal
fluid
obtain
flush
lung
ml
cold
pb
time
wash
step
repeat
lavag
fluid
recov
two
wash
pool
nasal
fluid
obtain
flush
nasopharynx
ml
cold
pb
time
nasal
wash
fluid
recov
mous
nostril
bal
nasal
fluid
centrifug
min
supernat
sampl
collect
sampl
store
subsequ
analysi
igg
iga
antibodi
detect
enzymelink
immunosorb
assay
elisa
follow
protocol
describ
joan
et
al
modif
briefli
microtit
plate
costar
corpor
usa
coat
recombin
protein
overnight
well
block
wv
bsa
h
sera
mucos
sampl
ad
incub
h
bound
antibodi
detect
use
hrpconjug
goat
antimous
igg
abcam
uk
dilut
hrpconjug
rat
antimous
iga
abcam
uk
dilut
plate
wash
time
pb
step
tmb
peroxidas
substrat
system
kpl
usa
ad
detect
incub
min
tmb
stop
solut
kpl
usa
ad
absorb
valu
nm
measur
use
micropl
reader
tecan
switzerland
assay
perform
technic
replic
stock
mous
adapt
influenza
viru
kindli
provid
dr
richard
j
webbi
st
jude
children
research
hospit
usa
day
follow
last
immun
mice
studi
group
b
fulli
anesthet
intraperiton
inject
ketaminexylazin
intranas
inocul
influenza
viru
inocul
bodi
weight
surviv
rate
mice
monitor
daili
day
mice
show
bodi
weight
loss
consid
reach
experiment
endpoint
euthan
intraperiton
inject
overdos
ketaminexylazin
advers
reaction
mortal
occur
outsid
human
endpoint
observ
throughout
studi
statist
analysi
graphic
represent
perform
use
graphpad
prism
softwar
graphpad
softwar
usa
data
analysi
perform
use
student
test
comparison
two
group
logrank
mantelcox
test
use
statist
comparison
surviv
group
l
lacti
surfac
display
recombin
protein
immunofluorescencelabel
alexa
fluor
percentag
alexa
fluor
gate
cell
l
lacti
surfac
display
increas
steadili
increas
amount
recombin
protein
ad
cfu
l
lacti
fig
percentag
alexa
fluor
gate
cell
reach
plateau
recombin
protein
use
result
suggest
optimum
amount
recombin
protein
incub
cfu
l
lacti
cell
surfac
display
percentag
l
lacti
surfac
display
recombin
protein
follow
incub
l
lacti
recombin
protein
h
h
h
h
examin
percentag
alexa
fluor
gate
cell
reach
plateau
recombin
protein
incub
l
lacti
cell
h
suggest
incub
h
optimum
surfac
display
recombin
protein
fig
bind
recombin
protein
l
lacti
start
dissoci
incub
period
h
suitabl
buffer
use
bind
recombin
protein
l
lacti
also
evalu
percentag
l
lacti
surfac
display
recombin
protein
h
incub
recombin
protein
pb
respect
suggest
number
l
lacti
cell
detect
cell
wall
similar
buffer
fig
therefor
mfi
valu
l
lacti
surfac
display
recombin
protein
examin
mfi
valu
obtain
recombin
protein
bind
significantli
higher
comparison
pb
suggest
recombin
protein
bound
per
l
lacti
cell
henc
better
bind
buffer
studi
group
preliminari
studi
evalu
immun
respons
toward
l
lacti
surfac
display
recombin
protein
serum
igg
iga
measur
main
readout
system
immun
differ
serum
igg
fig
iga
fig
mice
immun
mean
od
respect
compar
pbstreat
group
mean
od
respect
one
signific
outlier
detect
data
set
serum
iga
pbstreat
group
use
grubb
test
p
exclud
statist
analysi
overal
result
suggest
stimul
serolog
immun
respons
upon
oral
immun
mice
immun
respons
detect
limit
assay
siga
faecal
extract
small
intestin
wash
bal
fluid
nasal
fluid
measur
main
readout
mucos
immun
siga
faecal
sampl
fig
note
higher
statist
differ
mice
immun
mean
od
pbstreat
group
mean
od
data
set
small
intestin
wash
one
signific
outlier
detect
pbstreat
group
use
grubb
test
p
remov
statist
analysi
siga
small
intestin
wash
fig
mice
immun
mean
od
detect
significantli
higher
p
pbstreat
group
mean
od
data
set
bal
nasal
fluid
mice
immun
one
signific
outlier
detect
use
grubb
test
p
group
exclud
statist
analysi
siga
bal
fluid
fig
note
higher
statist
differ
mice
immun
mean
od
compar
pbstreat
group
mean
od
contrast
mice
immun
develop
significantli
higher
siga
nasal
fluid
p
mean
od
compar
pbstreat
group
mean
od
fig
collect
result
suggest
oral
immun
mice
stimul
signific
level
mucos
immun
gastrointestin
tract
respiratori
tract
studi
group
b
mice
immun
oral
fivefold
higher
dosag
determin
higher
dose
would
elicit
greater
immun
respons
comparison
addit
control
group
mice
includ
mice
oral
administ
recombin
protein
mice
subcutan
immun
emulsifi
freund
adjuv
signific
differ
serum
igg
fig
serum
iga
fig
mice
oral
immun
mean
od
respect
compar
pbstreat
group
mean
od
respect
observ
mice
oral
immun
recombin
protein
mean
od
respect
comparison
pbstreat
group
one
signific
outlier
detect
data
set
serum
iga
pbstreat
group
use
grubb
test
p
exclud
statist
analysi
anoth
signific
outlier
detect
data
set
serum
igg
mice
immun
use
grubb
test
p
remov
outlier
mous
show
detect
serum
igg
iga
respons
increas
subsequ
immun
also
signific
differ
serum
igg
iga
level
mice
oral
immun
contrast
significantli
highest
serum
igg
fig
iga
fig
p
detect
posit
control
group
mice
immun
subcutan
mean
od
respect
result
suggest
stimul
serolog
immun
respons
upon
oral
immun
mice
altern
respons
detect
limit
assay
nonetheless
subcutan
immun
mice
stimul
good
serolog
immun
respons
suggest
highli
antigen
significantli
higher
siga
fig
p
detect
faecal
sampl
mice
oral
immun
mean
od
pbstreat
group
mean
od
higher
dosag
administ
mice
effect
improv
mucos
immun
respons
clearli
indic
signific
stimul
siga
detect
faecal
sampl
fig
siga
faecal
sampl
mice
oral
immun
also
higher
statist
differ
compar
mice
immun
oral
mean
od
subcutan
mean
od
fig
signific
differ
detect
siga
faecal
sampl
mice
oral
immun
pbstreat
group
suggest
without
l
lacti
carrier
stimul
signific
level
siga
note
mice
immun
subcutan
compar
pbstreat
group
although
mice
immun
subcutan
stimul
good
serolog
immun
respons
howev
stimul
signific
level
siga
faecal
sampl
taken
togeth
result
suggest
potent
induc
mucos
immun
gastrointestin
tract
upon
oral
immun
mice
l
lacti
deliveri
platform
capabl
stimul
mucos
immun
gastrointestin
tract
day
follow
last
immun
mice
studi
group
b
challeng
intranas
influenza
viru
evalu
protect
efficaci
oral
administ
exposur
influenza
viru
chang
bodi
weight
surviv
mice
monitor
daili
measur
diseas
sever
nonimmun
mice
suscept
influenza
infect
show
sick
decreas
activ
huddl
day
postinfect
pi
sever
sick
hunch
postur
ruffl
fur
increas
bodi
weight
loss
observ
within
day
pi
fig
rate
bodi
weight
loss
calcul
linear
regress
analysi
maximum
percentag
chang
bodi
weight
observ
individu
mice
day
lethal
challeng
influenza
viru
tabl
contrast
bodi
weight
mice
group
decreas
day
pi
respect
mice
group
record
increas
bodi
weight
till
day
pi
fig
lower
rate
bodi
weight
loss
observ
group
respect
compar
nonimmun
mice
tabl
significantli
lower
percentag
chang
bodi
weight
note
p
group
p
nonimmun
mice
contrast
posit
control
group
mice
immun
subcutan
show
bodi
weight
loss
upon
exposur
influenza
viru
fig
mice
instead
record
rate
bodi
weight
gain
tabl
addit
significantli
lower
percentag
chang
bodi
weight
p
group
compar
nonimmun
group
tabl
data
indic
mice
oral
immun
result
significantli
less
morbid
upon
exposur
influenza
viru
mice
group
suffer
sever
sick
present
highest
rate
bodi
weight
loss
percentag
chang
bodi
weight
among
treat
group
subcutan
immun
mice
result
morbid
upon
exposur
viru
collect
demonstr
oral
immun
superior
reduc
morbid
upon
exposur
influenza
viru
compar
without
l
lacti
carrier
surviv
rate
immun
mice
upon
exposur
influenza
viru
assess
significantli
higher
surviv
rate
mice
observ
p
group
p
upon
exposur
influenza
viru
nonimmun
group
fig
tabl
surviv
rate
mice
immun
highest
significantli
differ
p
nonimmun
group
mice
fulli
protect
challeng
differ
surviv
immun
group
nonimmun
group
mice
protect
mean
day
death
pi
mean
day
death
group
pi
pi
respect
importantli
oral
immun
mice
subcutan
immun
provid
protect
anim
lethal
challeng
influenza
viru
influenza
viru
respiratori
pathogen
contribut
high
rate
morbid
mortal
human
global
antivir
therapi
avail
vaccin
still
effect
strategi
prevent
control
influenza
grow
interest
mucos
vaccin
due
advantag
convent
inject
vaccin
side
effect
associ
convent
vaccin
local
reaction
inject
site
potenti
reduc
implement
mucos
vaccin
need
needl
vaccin
administr
also
avoid
elimin
possibl
blood
transmiss
infect
moreov
mucos
vaccin
easili
administ
without
train
personnel
thu
consid
favor
approach
mass
vaccin
pathogen
includ
influenza
virus
initi
infect
enter
human
bodi
mucos
surfac
mucos
vaccin
stimul
natur
infect
provid
local
immun
protect
stimul
siga
mucos
surfac
siga
abund
immunoglobulin
isotyp
present
human
secret
effect
accord
protect
influenza
viru
infect
report
import
igg
protect
upper
respiratori
tract
specif
nose
trachea
primarili
reduc
viru
attach
prevent
intern
viru
mucos
surfac
therebi
prevent
infect
addit
siga
provid
crossprotect
subtyp
influenza
viru
crossprotect
particularli
desir
due
frequent
antigen
chang
influenza
virus
constantli
undergo
variou
mucos
immun
approach
l
lacti
explor
effect
vaccin
vehicl
previous
develop
recombin
l
lacti
display
influenza
evalu
immun
elicit
recombin
construct
mice
recombin
l
lacti
carri
gene
genet
introduc
vector
contain
antibiot
resist
gene
presenc
antibiot
resist
gene
could
eventu
matter
concern
particularli
transfer
antibiot
resist
gene
anoth
organ
l
lacti
releas
field
approach
util
nonrecombin
l
lacti
advantag
like
overcom
concern
henc
better
accept
public
subsequ
develop
nonrecombin
l
lacti
display
influenza
evalu
abil
stimul
mucos
immun
present
studi
present
studi
find
siga
faecal
extract
small
intestin
wash
bal
fluid
nasal
fluid
demonstr
oral
immun
mice
elicit
signific
level
mucos
immun
gastrointestin
tract
respiratori
tract
result
consist
previou
studi
show
oral
immun
l
lacti
display
antigen
induc
siga
site
gastrointestin
tract
result
siga
mucos
site
could
due
intestin
deriv
iga
plasma
cell
express
home
receptor
migrat
toward
cytokin
secret
mucos
epitheli
tissu
present
site
larg
intestin
stomach
trachea
bronchi
mammari
gland
salivari
gland
migrat
intestin
iga
plasma
cell
popul
mucos
site
secret
siga
therefor
oral
immun
could
lead
presenc
antigen
specif
iga
intestin
nonintestin
mucos
tissu
studi
group
b
higher
dosag
significantli
increas
specif
siga
respons
compar
nonimmun
group
result
suggest
siga
respons
elicit
could
improv
dosedepend
manner
observ
specif
siga
respons
upon
oral
immun
consist
previous
report
find
specif
siga
detect
upon
oral
immun
recombin
l
lacti
express
serum
igg
iga
almost
absent
follow
immun
except
one
mous
elicit
detect
serum
igg
iga
upon
administr
higher
dosag
result
obtain
contrast
sever
studi
demonstr
oral
immun
antigen
use
l
lacti
elicit
specif
igg
serum
addit
specif
siga
faecal
extract
although
mice
immun
oral
elicit
signific
mucos
immun
respons
system
immun
respons
importantli
demonstr
could
provid
protect
mice
lethal
challeng
influenza
viru
earlier
studi
mice
immun
oral
l
lacti
express
ha
influenza
show
signific
increas
specif
serum
igg
intestin
iga
iga
detect
tracheal
mucos
mice
protect
upon
viral
challeng
therefor
studi
protect
mice
like
due
presenc
siga
specif
respiratori
tract
possibl
activ
upon
oral
immun
would
benefici
evalu
neutral
abil
siga
induc
measur
capabl
inhibit
influenza
viru
vitro
howev
could
examin
due
limit
sampl
obtain
besid
siga
protect
mechan
cellmedi
immun
may
play
protect
role
clear
establish
infect
reduc
diseas
sever
therefor
addit
studi
need
elucid
specif
mechan
protect
nonetheless
find
obtain
highlight
import
mucos
immun
respiratori
tract
accord
protect
influenza
viru
challeng
compar
import
l
lacti
antigen
carrier
mice
immun
oral
show
markedli
improv
immun
respons
recombin
protein
without
l
lacti
mice
immun
also
suffer
less
sick
bodi
weight
loss
upon
lethal
challeng
influenza
viru
result
agreement
sever
earlier
studi
oral
immun
l
lacti
display
antigen
effici
simpl
antigen
alon
oral
immun
potenti
adjuv
effect
use
l
lacti
oral
immun
could
attribut
presenc
bacteri
compon
stimul
innat
immun
lead
adapt
immun
besid
l
lacti
present
heterolog
antigen
particl
immun
system
superior
solubl
antigen
present
particularli
vaccin
deliv
oral
present
studi
focus
protect
mice
homosubtyp
influenza
viru
challeng
heterosubtyp
influenza
viru
challeng
explor
investig
surfac
display
antigen
multipl
influenza
subtyp
singl
l
lacti
cell
candid
vaccin
render
protect
broad
rang
influenza
subtyp
also
perform
conclus
oral
administr
l
lacti
surfac
display
recombin
protein
induc
specif
siga
respons
mice
protect
homolog
influenza
viru
challeng
find
indic
applic
l
lacti
platform
vaccin
deliveri
import
mucos
immun
accord
protect
lethal
challeng
influenza
viru
